Status:
COMPLETED
Treatment of Acute Lymphoblastic Leukemia in Children
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Boston Children's Hospital
University of Rochester
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
1-18 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to reduce the side-effects from anti-leukemia therapy. The therapy in this study is based upon treatment information learned from prior clinical research programs as well ...
Detailed Description
* Children with acute lymphoblastic leukemia are treated somewhat differently depending on the relative risk of the leukemia recurring. Patients will be separated into "Standard Risk" and "High Risk"....
Eligibility Criteria
Inclusion
- Acute lymphoblastic leukemia excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin, L3 morphology, t(8;14) (q24;q32), t(8;22) or t(2;8)
- Age \> 12 months but less than 18 years
Exclusion
- Prior therapy except, 1 week of steroids, or emergent radiation therapy to the mediastinum
- Known HIV positive
Key Trial Info
Start Date :
September 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
498 Patients enrolled
Trial Details
Trial ID
NCT00165178
Start Date
September 1 2000
End Date
May 1 2011
Last Update
April 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115